- Market size and revenue benchmarking for a therapeutic asset in clinical development.
- Determine the appropriate launch curve to achieve full market penetration once a therapy is approved.
- Apply the appropriate “probability of success” to a clinical-stage pre-revenue biotech company.
- Apply key assumptions and tie together a long-range forecast of multiple products with a DCF analysis.
- Build-up of operating expenses including a salesforce analysis for a “go-it-alone” marketing strategy.
- Key learning objectives include
- Overview of a sum of the parts valuation
- Major building blocks for a biotech SOTP
- Model assumptions dashboard
- Biotech company lifecycle
- Identify peak revenue opportunity
- Therapeutic areas overview
- Product launch timing and uptake curve
- Patent life and loss of exclusivity
- Road to commercialization
- FDA clinical trials
- Building a commercial infrastructure
- Completing the SOTP
- Probability of success
- Finalizing the valuation model
- Valuation sensitivities
Where
This is an online event.CFA Society of Columbus WSP - Build a Sum-of-the-Parts Valuation for a Biotech
Build a Sum-of-the-Parts Valuation for a Biotech
-
Value a Pre-Revenue BiotechWant to value a clinical-stage, pre-revenue biotech? An ordinary discounted cash flow analysis won’t cut it. Instead, you need to build a long-range sum-of-the-parts valuation.
This advanced virtual "Power Session" walks participants through the step-by-step process of valuing a biotech company
- Taught by Experienced ProfessionalsThis is NOT an academic exercise. It is taught by a healthcare-focused investment banking professional who understands how SOTP valuation is done on the job.
What You'll Learn